Related Experiment Video

Updated: Jan 10, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

2.1K

IgA nephropathy new therapies: from data in adults to application in children

Alexandra Cambier1,2,3, Lison Lachize Neanne2,3, Srishti Sahu2,3

  • 1Service de Néphrologie Pédiatrique-Hémodialyse, CHU Sainte Justine, Montréal, Canada.

Pediatric Nephrology (Berlin, Germany)
|November 20, 2025
PubMed

Insights

IgA nephropathy (IgAN) is a common kidney disease. New therapies targeting gut mucosal IgA1 synthesis and complement pathways show promise for slowing IgAN progression, especially in young patients.

Area of Science:

  • Nephrology
  • Immunology

Background:

  • IgA nephropathy (IgAN) is the most common primary glomerulonephritis, frequently affecting children and young adults.
  • IgAN can lead to kidney failure, with current treatments offering limited efficacy.
  • Novel therapies are emerging to target specific disease pathways.

Purpose of the Study:

  • To review the key pathological pathways in IgA nephropathy.
  • To present advanced, targeted therapies currently under development for IgAN.
  • To discuss the potential application of these novel treatments in pediatric IgAN cases.

Main Methods:

  • Literature review of IgA nephropathy pathogenesis.
  • Analysis of emerging therapeutic strategies targeting specific disease mechanisms.
  • Evaluation of clinical trial data for novel IgAN treatments.

Main Results:

  • Key pathways targeted include gut mucosal GdIgA1 synthesis and complement system activation (lectin and alternative pathways).
  • Therapies involve B cell modulation and complement protein inhibition.
  • Emerging treatments demonstrate potential in reducing proteinuria and stabilizing GFR.

Conclusions:

  • Targeted therapies offer a promising new avenue for IgAN management.
  • These novel treatments may improve outcomes, particularly in younger patients.
  • Further research is warranted to fully establish the efficacy and safety of these advanced IgAN therapies.

Keywords:
Chronic kidney diseaseIgA nephropathyNovel therapiesPediatrics

More Related Videos

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.2K
An Efficient Sieving Method to Isolate Intact Glomeruli from Adult Rat Kidney10:14

An Efficient Sieving Method to Isolate Intact Glomeruli from Adult Rat Kidney

Published on: November 1, 2018

14.4K

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
249
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
326
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
536